BrightPath Biotherapeutics Co., Ltd.

4594

JP3274140007

Biotechnology & Medical Research

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-05-28 am EDT			5-day change	1st Jan Change
57 ^JPY	0.00%		-3.39%	-34.48%

2023	BrightPath Biotherapeutics Co., Ltd. announced that it has received ¥5.1678 million in funding from Macquarie Group Limited	CI
2023	BrightPath Biotherapeutics Co., Ltd. announced that it expects to receive ¥5.1678 million in funding from Macquarie Group Limited	CI

BrightPath Biotherapeutics Co., Ltd. has filed an IPO.

September 14, 2015 at 12:00 am EDT

BrightPath Biotherapeutics Co., Ltd. has filed an IPO.

Security Name: Shares
Security Type: Common Stock
Securities Offered: 12,552,900

Transaction Features: Sponsor Backed Offering

Latest news about BrightPath Biotherapeutics Co., Ltd.

BrightPath Biotherapeutics Co., Ltd. announced that it has received ¥5.1678 million in funding from Macquarie Group Limited	Nov. 29	CI
BrightPath Biotherapeutics Co., Ltd. announced that it expects to receive ¥5.1678 million in funding from Macquarie Group Limited	Nov. 13	CI
BrightPath Biotherapeutics Co., Ltd.(TSE:4594) dropped from S&P Global BMI Index	22-09-19	CI
BrightPath Biotherapeutics Presents Data on Personalized Neoantigen Cancer Vaccine	22-04-13	MT
BrightPath Biotherapeutics Presents Data on Antibody for Cancer Treatment	22-04-13	MT
Brightpath Biotherapeutics Announces Preclinical Data on BP1209	22-04-12	CI
BrightPath Biotherapeutics Co., Ltd. announced that it has received ¥1.427175 billion in funding from Macquarie Bank Limited, Investment Arm	22-01-31	CI
BrightPath Biotherapeutics Co., Ltd. announced that it expects to receive ¥1.427175 billion in funding from Macquarie Bank Limited, Investment Arm	22-01-13	CI
BrightPath Biotherapeutics Co., Ltd. announced that it has received ¥0.585974 million in funding from Merrill Lynch Japan Securities Co., Ltd., Investment Arm	20-04-22	CI
BrightPath Biotherapeutics Co., Ltd. announced that it expects to receive ¥0.585974 million in funding from Merrill Lynch Japan Securities Co., Ltd., Investment Arm	20-04-06	CI
Brightpath Biotherapeutics Co., Ltd. Reports Consolidated Earnings Results for the Six Months Ended September 30, 2018; Provides Consolidated Earnings Guidance for the Year Ending March 31, 2019	18-11-09	CI
Brightpath Biotherapeutics Co., Ltd. Reports Consolidated Earnings Results for the First Quarter Ended June 30, 2018; Provides Earnings Guidance for the Year Ending March 31, 2018	18-08-10	CI
BrightPath Biotherapeutics Co., Ltd. Reports Consolidated and Non-Consolidated Earnings Results for the Year Ended March 31, 2018; Provides Consolidated Earnings Guidance for the Year Ending March 31, 2019	18-05-11	CI
BrightPath Biotherapeutics Co., Ltd. Reports Consolidated Earnings Results for the Third Quarter Ended December 31, 2017; Provides Consolidated Earnings Guidance for the Year Ending March 31, 2018	18-02-14	CI
BrightPath Biotherapeutics Co., Ltd. announced that it has received ¥12.1744 million in funding from Credit Suisse Securities Limited, Investment Arm	17-12-07	CI
BrightPath Biotherapeutics Co., Ltd. announced that it expects to receive ¥12.17 million in funding from Credit Suisse Securities Limited, Investment Arm	17-11-21	CI
Brightpath Biotherapeutics Co., Ltd. Reports Consolidated Earnings Results for the Six Months Ended September 30, 2017; Provides Consolidated Earnings Guidance for the Year Ending March 31, 2018	17-11-10	CI
BrightPath Biotherapeutics Co., Ltd. Reports Consolidated Earnings Results for the First Quarter Ended June 30, 2017; Provides Earnings Guidance for the Year Ending March 31, 2018	17-08-14	CI
BrightPath Biotherapeutics Enters into Licensing Agreement with University of Tokyo	17-07-23	CI
GreenPeptide Co., Ltd. Reports Consolidated and Non-Consolidated Earnings Results for the Year Ended March 31, 2017; Provides Earnings Guidance for the Year Ending March 31, 2018	17-05-12	CI
GreenPeptide Co., Ltd. Reports Consolidated Earnings Results for the Third Quarter Ended December 31, 2016, Provides Earnings Guidance for the Year Ending March 31, 2017	17-02-10	CI
GreenPeptide Co., Ltd. Announces Notice of Initiation of Phase II Clinical Trial of GRN-1201	17-01-27	CI
Advanced Immunotherapy Co., Ltd. announced that it has received funding from GreenPeptide Co., Ltd.	16-11-30	CI
Advanced Immunotherapy Co., Ltd. announced that it expects to receive funding from GreenPeptide Co., Ltd.	16-11-19	CI
GreenPeptide Co., Ltd. Reports Non-Consolidated Earnings Results for the Six Months Ended September 30, 2016; Provides Earnings Guidance for the Year Ending March 31, 2017	16-11-11	CI

Chart BrightPath Biotherapeutics Co., Ltd.

Duration

Period

Chart BrightPath Biotherapeutics Co., Ltd.

More charts

BrightPath Biotherapeutics Co., Ltd. is a Japan-based company mainly engaged in the development of pharmaceutical products. The Company is a biopharmaceutical venture company focused on developing cancer immunotherapeutic. The Companies business model covers drug discovery research and early clinical development of cancer immunotherapy; conducting of early-phase clinical trials; and development, manufacturing, and launching of the drugs as commercial products in Japan and abroad. The Company also generates the revenues from license fees from the pharmaceutical companies.

Sector

Biotechnology & Medical Research

Calendar

2024-08-08 - Q1 2024 Earnings Release (Projected)

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
BRIGHTPATH BIOTHERAPEUTICS CO., LTD.	-34.48%	25.79M
MODERNA, INC.	+54.05%	63.85B
IQVIA HOLDINGS INC.	-2.02%	41.83B
LONZA GROUP AG	+40.01%	40.47B
CELLTRION, INC.	-10.22%	27.17B
ICON PUBLIC LIMITED COMPANY	+13.42%	26.52B
ALNYLAM PHARMACEUTICALS, INC.	-21.60%	18.69B
BIO-TECHNE CORPORATION	+2.89%	12.73B
UNITED THERAPEUTICS CORPORATION	+22.40%	12.11B
MEDPACE HOLDINGS, INC.	+27.49%	12.07B

Other Biotechnology & Medical Research